ALNY Alnylam Pharmaceuticals

• None no insider bought on the open market
• None no sales outside a trading plan
• $24.1M sold by 5 insiders under 10b5-1 plans

1. Insider
   Trade
   Value
   Traded, filed
2. David E I Pyott Director
   Planned sale
   $1.1M 3,830 shares at $299.18 71% of stake
   Traded Jun 1 Filed Jun 3
   ↗
3. Melissa McLaughlin Chief Human Resources Officer
   Planned sale
   $755K 2,286 shares at $330.42 20% of stake
   Traded Apr 6 Filed Apr 7
   ↗
4. Pushkal Garg EVP Chief R&D
   Planned sale
   $779K 2,404 shares at $323.96 11% of stake
   Traded Mar 5 Filed Mar 6
   ↗
5. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
   Planned sale
   $213K 658 shares at $323.98 3.1% of stake
   Traded Mar 5 Filed Mar 6
   ↗
6. Pushkal Garg EVP Chief R&D
   Planned sale
   $568K 1,775 shares at $319.74 7% of stake
   Traded Mar 3 Filed Mar 4
   ↗
7. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
   Planned sale
   $528K 1,652 shares at $319.73 7% of stake
   Traded Mar 3 Filed Mar 4
   ↗
8. Pushkal Garg EVP Chief R&D
   Planned sale
   $1.5M 4,627 shares at $331.34 17% of stake
   Traded Feb 27 Filed Mar 2
   ↗
9. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
   Planned sale
   $678K 2,041 shares at $331.96 8.8% of stake
   Traded Feb 17 Filed Feb 17
   ↗
10. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
    Planned sale
    $848K 2,290 shares at $370.33 9.7% of stake
    Traded Jan 13 Filed Jan 14
    ↗
11. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
    Planned sale
    $5.5M 12,128 shares at $452.18 36% of stake
    Traded Nov 17, 2025 Filed Nov 19, 2025
    ↗
12. Yvonne Greenstreet CEO
    Planned sale
    $11.6M 25,650 shares at $452.75 28% of stake
    Traded Nov 12–13 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 210 sales to cover taxes, 27 stock grants, 14 option exercises, and 1 share withholding for taxes.